Survodutide and the liver: why glucagon matters for MASH research

In SYNCHRONIZE-MASLD, a phase 3 trial reported in Nature Medicine in 2026, 84.2% of participants on survodutide had their liver fat content fall by at least 30% after 48 weeks, against 24.3% on placebo. The same trial showed a 12.2% mean body-weight reduction. Survodutide is a dual agonist at the glucagon and GLP-1 receptors, and the glucagon side of that pairing is the reason this compound's research program leans so heavily on the liver, not just the scale.

What does survodutide do for weight, on its own?

Two large phase 3 trials, both published in the New England Journal of Medicine in 2026 and funded by Boehringer Ingelheim, establish the weight-loss baseline. SYNCHRONIZE-1 randomized 725 adults with obesity but without diabetes to survodutide 3.6 mg, 6.0 mg, or placebo for 76 weeks. Using the treatment-regimen estimand, mean weight change was -12.2% at 3.6 mg and -13.0% at 6.0 mg, against -5.4% on placebo (P<0.001 for both doses versus placebo); at least 5% weight loss was reached by about 72% of participants on either dose versus 46.3% on placebo. SYNCHRONIZE-2, in 752 adults with obesity and type 2 diabetes, found a smaller effect: -8.2% at 3.6 mg and -9.8% at 6.0 mg, against -3.9% on placebo, with HbA1c falling 0.9 and 0.8 percentage points versus 0.2 on placebo. Gastrointestinal adverse events, generally mild to moderate, occurred in 73-78% of survodutide participants in SYNCHRONIZE-2 and 81-90% in SYNCHRONIZE-1, versus 39% and 48% on placebo.

What did SYNCHRONIZE-MASLD add on the liver?

SYNCHRONIZE-MASLD enrolled 216 adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD), including participants with biopsy-confirmed MASH, and randomized them 2:1 to survodutide 6.0 mg or placebo for 48 weeks. The co-primary endpoints were a 30% or greater reduction in MRI-measured liver fat content and percent body-weight change, and both were met. Using the efficacy estimand, 84.2% of the survodutide group reached the liver-fat threshold versus 24.3% on placebo (P<0.0001); the more conservative treatment-regimen estimand, which counts everyone regardless of whether they stayed on treatment, still showed 68.5% versus 28.6%. Weight change was -12.2% with survodutide versus -1.0% with placebo under the efficacy estimand. The trial authors note two limits: it ran only 48 weeks, and it recruited only in the United States and Spain.

Does the liver benefit need the weight loss?

This is where the glucagon-receptor rationale gets tested directly. A post hoc mediation analysis of survodutide's earlier phase 2 MASH trial (NCT04771273, 170 participants with biopsy-confirmed fibrosis stage F2-F3) split the drug's effect into a portion that worked through weight loss and a portion that did not. For the histological endpoints, weight loss accounted for an estimated 66.7% of the effect on resolving MASH without worsening fibrosis and 71.8% of the effect on improving MASH without worsening fibrosis, meaning roughly a third of those effects were weight-independent. For improvement in fibrosis without worsening of MASH, weight loss explained only 36.3% of the effect, leaving a majority attributable to something else. Non-invasive markers of inflammation and fibrosis showed a similar pattern: weight loss explained less than half the total effect, from 16.5% (AST) to 38.6% (Enhanced Liver Fibrosis score). Steatosis-related measures told a different story, with weight loss explaining a majority of the effect (58.2% for MRI-measured fat content, 77.4% for FibroScan's Controlled Attenuation Parameter). The authors read this pattern as evidence of a direct glucagon-receptor action in the liver, separate from appetite suppression.

What is the regulatory status, and who develops it?

Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for global development and commercialization and Zealand retaining a co-promotion right in the Nordic countries. The FDA granted survodutide Breakthrough Therapy designation on October 8, 2024, specifically for noncirrhotic MASH with moderate or advanced fibrosis (stages 2 or 3); that designation speeds FDA interactions during development but is not an approval. As of this writing (verified 2026-10-08), we found no approval for survodutide from the FDA or any other regulator in the sources we opened. On the liver side, the HCPLive report names two phase 3 trials, LIVERAGE (about 1,800 adults with MASH and stage 2-3 fibrosis) and LIVERAGE-Cirrhosis (about 1,590 adults with compensated cirrhosis). For obesity, SYNCHRONIZE-CN is a 76-week phase 3 trial in Chinese adults; its published baseline paper describes 306 participants and reports no efficacy results yet. For the broader receptor biology, see mazdutide, a related GLP-1/glucagon dual agonist with its own separate trial program.

Bottom line

Survodutide's phase 3 obesity trials produced a mean 13.0% weight loss at the 6.0 mg dose over 76 weeks in adults without diabetes, versus 5.4% on placebo. What sets the liver program apart is the mediation analysis: it points to a glucagon-receptor effect on fibrosis and inflammation markers that does not simply track body-weight change. That is a mechanistic hypothesis supported by post hoc statistics, not a confirmed clinical benefit independent of weight loss, and it needs replication in the ongoing phase 3 LIVERAGE program before it can be treated as established. Survodutide remains investigational, and we found no approval for obesity or liver disease. See the survodutide profile for compound details.